Number of Shares
0
Previous 0 NaN%
Holding current value
$0
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 10, 2024

BUY
$15.61 - $23.34 $0 - $0
0 New
0 $0
Q2 2024

Jul 23, 2024

BUY
$11.83 - $24.05 $0 - $0
0 New
0 $0
Q1 2024

Apr 30, 2024

SELL
$12.42 - $17.29 $86 - $121
-7 Closed
0 $0
Q4 2023

Feb 07, 2024

BUY
$11.13 - $15.78 $66 - $94
6 Added 600.0%
7 $0
Q3 2023

Oct 25, 2023

SELL
$16.15 - $42.35 $1,195 - $3,133
-74 Reduced 98.67%
1 $0
Q4 2022

Jan 30, 2023

BUY
$63.98 - $85.37 $4,798 - $6,402
75 New
75 $0
Q3 2022

Nov 15, 2022

SELL
$67.99 - $89.57 $8,498 - $11,196
-125 Closed
0 $0
Q1 2022

May 09, 2022

SELL
$60.15 - $84.52 $19,308 - $27,130
-321 Reduced 71.97%
125 $10,000
Q4 2021

Feb 07, 2022

BUY
$75.08 - $121.99 $300 - $487
4 Added 0.9%
446 $33,000
Q3 2021

Nov 09, 2021

BUY
$116.17 - $194.55 $27,067 - $45,330
233 Added 111.48%
442 $51,000
Q4 2020

Feb 02, 2021

SELL
$112.16 - $174.14 $2,018 - $3,134
-18 Reduced 7.93%
209 $36,000
Q1 2020

May 13, 2020

BUY
$57.05 - $95.75 $285 - $478
5 Added 2.25%
227 $15,000
Q4 2019

Feb 14, 2020

BUY
$68.3 - $93.8 $887 - $1,219
13 Added 6.22%
222 $19,000
Q3 2019

Nov 13, 2019

BUY
$61.86 - $97.8 $7,979 - $12,616
129 Added 161.25%
209 $16,000
Q2 2019

Aug 13, 2019

BUY
$42.22 - $63.23 $3,377 - $5,058
80 New
80 $5,000
Q1 2019

May 15, 2019

BUY
$31.96 - $56.12 $0 - $0
0 New
0 $0
Q4 2018

Feb 14, 2019

BUY
$28.72 - $52.63 $0 - $0
0 New
0 $0
Q3 2018

Nov 13, 2018

BUY
$32.0 - $52.4 $0 - $0
0 New
0 $0

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.04B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Concourse Financial Group Securities, Inc. Portfolio

Follow Concourse Financial Group Securities, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.